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Abstract - Hypocellular or hypoplastic myelodysplastic 
syndromes (HMDS) are a distinct subgroup accounting for  
10–15% of all MDS patients, that are characterized by the 
presence of bone marrow (BM) hypocellularity, various 
degree of dysmyelopoiesis and sometimes abnormal 
karyotype.  
 Laboratory and clinical evidence suggest that HMDS 
share  several immune-mediated pathogenic mechanisms 
with acquired idiopathic aplastic anemia (AA).  
 Different immune-mediated mechanisms have been 
documented in the damage of marrow hematopoietic 
progenitors occurring in HMDS; they include oligoclonal 
expansion of cytotoxic T lymphocytes (CTLs), polyclonal 
expansion of various subtypes of T helper lymphocytes, 
overexpression of FAS-L and of the TNF–related apoptosis-
inducing ligand (TRAIL),  underexpression of Flice-like 
inhibitory protein long isoform (FLIPL) in marrow cells as 
well as higher release of Th1 cytokines, such as interferon-
gamma (IFN-γ) and  tumor necrosis factor-alpha (TNF-α).  
It has also been documented that some HMDS patients have 
higher frequency of polymorphisms linked both to high 
production of proinflammatory cytokines such as TNF-α 
and  transforming growth factor-β and to the inhibition of 
T-cell mediated immune responses such as interleukin-10, 
further suggesting that immune-mediated mechanisms 
similar to those seen in AA patients may also operate in 
HMDS.  
 Clinically, the strongest evidence for immune–mediated 
hematopoietic suppression in some HMDS is the response to 
immunosuppression including  mainly cyclosporine, anti-
thymocyte globulin and/or cyclosporine, or alemtuzumab. 
 Here we review all these immune mechanisms as well as 
the  influence of this deranged cellular and humoral 
immunologic mileau on the initiation and possible 
progression of MDS. All these observations are pivotal  not 
only for a better understanding of MDS pathophysiology, 
but also for their immediate clinical implications, eventually 
leading to the identification of MDS patients who may 
benefit from immunosuppression. 
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I. OVERLAPPING AND DIFFERENCIAL FEATURES 
BETWEEN APLASTIC ANEMIA, HYPOCELLULAR 
AND NORMO/HYPERCELLULAR MDS 
 
 Myelodysplastic syndromes (MDS) are a 
heterogeneous group of diseases characterized by 
impairment of cellular differentiation (also defined as 
ineffective hematopoiesis) progressive peripheral 
cytopenias and increased risk of developing acute myeloid 
leukemia (AML) [1]. Although the French-American-
British (FAB) and World Health Organization (WHO) 
classification systems do not take into account hypoplastic 
or hypocellular myelodysplastic syndromes (HMDS) as a 
defined category of MDS, being HMDS probably 
considered the expression of a transitional status of other 
MDS categories, they appear to be a distinct 
clinicopathologic entity [2].  
HMDS accounts for 10–15% of all MDS [3-5] and 
are characterized  by the following features: age-corrected 
bone marrow hypoplasia (ie cellularity less than 30% 
under age of 60 years or cellularity less than 20% for 
older than 60 years) [4], marked dyserythropoiesis, both 
dysgranulopoiesis and dysmegakariopoiesis [4,5],  macro-
cytosis, severe neutropenia and thrombocytopenia [3-6], 
frequent abnormal karyotype [6-8], low rate of 
progression to acute leukemia, and poor response to 
conventional therapeutic approach for MDS [6].   
Recently, Bennett and Orazi described several others 
marrow morphological criteria, detectable by bone biopsy 
histological analysis, useful to help HMDS diagnosis, 
such as the presence of dysplastic megakaryocytes [4-5] 
within the disorganized microarchitecture of MDS 
marrow [4], the detection of fibrosis [4,8], and the 
immunohistochemical identification of aggregates or 
clusters of blasts in the central intertrabecular region of 
marrow, also defined as abnormally localized immature 
myeloid precursor cells (ALIP) [4,5,9-10].  
According to FAB and WHO classification systems, 
the majority of HMDS cases fall into refractory anemia 
(RA) and refractory cytopenias with multilineage 
dysplasia (RCMD)  categories [3-8].  In comparison to 
RA and RCMD, HMDS patients typically are younger, 
more frequently display a severe neutropenia and 
thrombocytopenia and a lower percentage of blasts, as 
well as even less frequently show karyotypically 
abnormal dysplastic marrow cells.  Although Tuzuner et 
al. documented no difference in prognosis between 
HMDS and  normo-/hypercellular MDS [11], several 
other studies have reported a more favorable overall 
survival in  the subgroup of HMDS patients [6,8,12].  
The distinction between HMDS and AA is even more 
problematic than that with RA and RCMD when marrow 
is sparcely cellular with an overall cellularity less than 
20%  and when these findings are associated with the 
presence of mast cells and reactive lymphocytes, 
sometimes organized in small lymphoid clusters, similar 
to those observed in AA bone marrow biopsies [4,5].  
The presence of a clear dysmegakaryopoiesis and 
dysgranulopoiesis, but not of a mild isolated 
dyserythropoiesis, usually also found in AA, the detection 
of karyotypic and fluorescent in situ hybridization (FISH) 
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abnormalities, as well as the identification of any 
sideroblast, of clusters of blasts, and of an increased 
number of marrow fetal hemoglobin (HbF)-positive 
erythroblasts, distinctly address toward a diagnosis of 
HMDS [13].   
However, recognized HMDS karyotypic and FISH 
abnormalities, such as trisomy 8, trisomy 1q, 20q deletion 
and monosomy 7, can be also be found, although less 
frequently, in AA patients in particular throughout their 
clinical course [6-8].  Additional clonal molecular defects 
such as mutations in the RNA component of telomerase 
(TERC) or in the telomerase reverse transcriptase enzyme 
(TERT) genes and several other microdeletions,  assessed  
by single nucleotide polymorphism (SNP) array–based 
karyotyping, have  been documented in both HMDS and 
AA patients [14].  
The separation of AA and HMDS is even more difficult 
when clonal cytogenetic markers are absent.  
Quantification of marrow CD34
+
 cells by 
immunohistochemistry and flow-cytometry has been 
reported to help in distinguishing between AA and HMDS 
[15-20]. Matsui et al. have demonstrated that the mean 
percentage of CD34
+
 cells in AA patients is significantly 
lower than those of HMDS patients [15]. Noteworthy, we 
previously documented that, in addition to the defect in 
more mature committed progenitor cells, also most 
immature hematopoieitic stem cells, measured as 
secondary colony-forming cells (CFC) after 5 weeks of 
long-term bone marrow culture (LTBMC), were affected 
by disease process in HMDS [18,19].  However, although 
marrow and circulating CD34
+
 cells and secondary CFC 
numbers were significantly higher in HMDS than  in AA, 
we found that  there was a high degree of overlap between 
these two diseases, clearly demonstrating that secondary 
CFC numbers in either marrow and  peripheral blood 
could not help to distinguish AA from HMDS in an 
individual patient [17,18].  
Recently, Tripathi et al. also reported that circulating 
blood lymphocytes of AA patients had significantly lower 
S-phase fraction (SPF) and aneuploidy in comparison to 
HMDS patients, suggesting that SPF and aneuploidy 
could be a further parameter to differentiate AA from 
HMDS patients [21]. 
In addition, we documented that HMDS and RA 
patients show a severe deficit in marrow and circulating 
committed (CD34
+
 cells and primary CFC),  and 
immature progenitor cells (such as secondary CFC), 
compared to normal donors, implying that immature 
hematopoietic stem cell compartment is affected by 
disease process in HMDS.  However, despite the dramatic 
difference in marrow cellularity, both more committed 
and immature progenitor cells showed no significant 





II. IMMUNOLOGIC DERANGEMENT IN MDS AND 
HMDS 
 
It is widely recognized that genetic, epigenetic, 
apoptotic and differentiation abnormalities characterizing 
MDS hematopoietic progenitors may be initiated and/or 
supported by a significant derangement of immunological 
microenvironment in some MDS patients. The immune 
effector mechanisms involved in the complex 
physiopathology of MDS include not only marrow and 
circulating  immune cell changes, but also  dysregulation 
in their cytokine expression and release. The role of the 
 
Figure 1. Severe deficit of marrow and circulating CD34+ cells and secondary CFC in HMDS and RA patients. Each bar represents mean 
progenitors ± SD of progenitor cells in  normal controls (n=20), in tot HMDS (n=11)  and in RA (n=20) patients. Figure 1A. Mean circulating CD34+ 
cells in normal controls, in HMDS, and RA patients: 113±12, 54±11 and 64±8, respectively; p < 0.05 between normal control vs HMDS and RA 
patients, p > 0.05 between HMDS and RA patients; mean bone marrow (BM) CD34+ cells in normal controls, in HMDS, and RA patients: 135.6±21, 
15.4±4.2 and 23.2±4.7, respectively; p < 0.05 between normal control vs HMDS and RA patients, p > 0.05 between HMDS and RA patients. Figure 
1B. Mean circulating secondary CFC in normal controls (n=12), HMDS (n=18) and RA (n=30) patients: 16.6±2.5, 5.9±3.4 and 12.0±3.6, respectively; 
p < 0.05 between normal control vs HMDS and RA patients, p > 0.05 between HMDS and RA patients; and mean BM secondary CFC in normal 
controls, HMDS and RA patients: 146.6±38.0, 17.5±6.4 and 21.2±6.6, respectively; p < 0.05 between normal control vs HMDS and RA patients, p > 
0.05 between HMDS and RA patients.   
Abbreviations. CFC = colony-forming cells; HMDS = hypoplastic myelodysplastic syndrome; MNC = mononuclear cells; TNC = total nucleated cells; 
PB = peripheral blood; RA = refractory anemia. Statistical analysis: Student t test [see ref. 17-18].
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main changes in the immune cell compartment and in the 
cytokine profile in MDS, including HMDS, is discussed 
below. 
 
Effector immune cell changes 
Similar to AA, it has been recently documented  by 
several authors, using different T-cell-receptor (TCR) 
repertoire molecular analysis techniques, that oligoclonal 
expansion of cytotoxic T cells (CTL) expressing specific 
TCR variable beta (Vβ) chain, with unique hypervariable 
complementarity determining region 3 (CDR3), is 
detectable in blood and marrow of some MDS patients, 
regardless of the presence of a hypocellular or 
normo/hypercellular MDS marrow [23,24].  
It has been reported that some MDS patients may 
show a decrease of such immunodominant CTL 
clonotypes after immune-suppressive treatment 
concurrently with blood count improvement, suggesting 
that these CTL clonotypic-specific assays may be used for 
monitoring disease activity and response to 
immunosuppressive therapy [25,26].  
The presence of these dominant T-cell clonotypes in 
blood and marrow of about 90% of MDS patients, as well 
as the documentation that the number of TCR-Vβ families 
with skewed CDR3 constitutes about 10% of the total T-
cell population in MDS patients, suggest that these 
dominant clonal CTL in MDS are likely the result of an 
antigen-driven dominant immune response, and  
hypothesize their pivotal pathophysiologic role in T-cell 
mediated inhibition of hematopoietic progenitors in MDS 
patients [24-26]. Formal proof of this hypothesis has been 
achieved in AA patients, showing that these dominant T-
cell clonotypes exert potent cytotoxicity against AA 
autologous marrow progenitor cells, but  have not been 
demonstrate in MDS so far due to the difficulty of 
obtaining sufficient numbers of autologous target MDS 
cells [22,23]. 
The antigens driving the immune attack on 
hematopoietic progenitors of AA and possibly of some 
MDS patients could be similar, but unfortunately they  are 
remain unknown, as well as the possible primary 
abnormalities of hematopoietic progenitors leading to the 
breaking of immune self-tolerance [24,27]. 
Recently, Sloand et al. have documented increased 
numbers of Vβ CTL subfamilies in marrow and blood of 
MDS with trisomy 8, suggesting that these 
immunodominant CTL, able to selectively kill trisomy 8 
MDS cells in vitro, may account for the higher 
responsiveness of MDS patients with trisomy 8 to 
immunosuppressive therapy, compared with other MDS 
subtypes [6,28,29].  
Furthermore, Sloand et al. have demonstrated, by 
microarray analysis [30],  that CD34
+
 MDS cells with 
trisomy 8 overexpress the Wilms tumor protein 1 (WT1) 
and that circulating CD8
+
 CTL cells, recognizing WT1126–
134 peptides, may be detected, by tetramer analysis, in this 
MDS population, suggesting that WT1 may operate as a 
neoantigen on trisomy 8 MDS cells triggering the 
expansion of WT1-specific CD8
+
 T cells and leading to 
autoimmune suppression of MDS clone and likely of 
residual normal marrow cells [27,30,31]. However, it is 
not possible to exclude that other neoantigens or the 
overexpression of other self-antigens presented by 
trisomy 8 MDS cells,  such as neutrophil elastase (NE), 
proteinase 3 (P3) and the human leukocyte antigen 
(HLA)-A2 restricted nonameric peptide (PR1), detectable 
also in other myeloid malignant cells, might elicit the 
expansion of such antigens-specific CD8
+
 CTL [29,31]. 
Two main pathways in CTL-mediated cytotoxicity 
have been described: Ca
2+
-dependent perforin/granzyme-
mediated apoptosis, and Ca
2+
-independent Fas ligand 
(FAS-L)/Fas-receptor (Fas-R) mediated apoptosis [32-
37]. Previously, we have reported that Fas-L is slightly 
increased on CD3+ cells of HMDS and RA patients, 
compared with normal controls [17]. Moreover, we and 
others have documented that CD34
+
 cells of HMDS, as 
well as of low/intermediate-1 risk and trisomy 8 MDS 
patients, overexpress Fas-R further suggesting a central 
role of Fas-L/Fas-R-mediated apoptosis in ineffective 
hematopoiesis of some MDS [17,28,32].  However, we 
did not found any differential sensitivity of circulating 
and marrow hematopoietic progenitors patients to  Fas-L 
between RA and HMDS in vitro, supporting the  
hypothesis that similar mechanisms for CD34
+
 cell 
impairment may be involved in these two diseases [17].  
Recently, it has also been reported that decreased 
expression of Fas-R, or Fas-associated via death domain 
(FADD), detected when low-risk MDS progress to AML, 
may be related to FAS gene silencing mediated by DNA 
methylation at nuclear factor kB (NF-kB) binding sites 
[38]. 
Several abnormalities have been also reported within 
various CD4
+
 subsets in MDS patients, including HMDS 
[3,6,39].  Similar to CTL, increased number of individual 
Vβ subfamilies have been detected in CD4
+
 T cells of 
MDS patients, independent of their International 
Prognostic Scoring System (IPSS) category; conversely to 
CTL, CD4
+
 T cells do not show increased frequencies of 
CDR3 immunodominant clones, indicating that expanded 
Vβ subfamilies are polyclonal in MDS patients [40].  
We and others previously found that CD4
+
 T helper 
(Th) cells producing interferon-gamma (IFN-γ), playing a 
central role in promoting and maintaining CTL responses 
in several immune-mediated diseases, are increased in 
HMDS and low-risk MDS patients, compared to healthy 
controls; however, a high degree of overlap in IFN-γ 
producing CD4
+




 T helper cell subsets,  such as  regulatory 
T-cells (Treg), Th17 and Th22, regulating CTL activity, 
have been described contributing to derangement of 
immunological microenvironment in MDS [42-46]. 
Impaired proliferative capacity and bone marrow 
trafficking of Treg, implying an enhancement of 
autoimmune processes, have been documented in low-risk 
MDS [47-51]. By contrast, high-risk MDS show increased 
Treg numbers, resulting in deficient anti-tumor immunity, 
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Figure 2. Main pathways involved in immune-mediated apoptosis of hematopoietic progenitor cell compartment in lower risk MDS and in 
immune-escape of MDS clone in higher risk MDS.  See paragraph II, immunologic derangement in HMDS and MDS for  details.  
Abbreviations. APAF-1 = apoptotic protease activating factor-1; CM Treg = central memory T regulatory cell; CTL = cytotoxic T lymphocyte; DC = 
dendritic cell; EM Treg = effector memory T regulatory cell; FADD = Fas-Associated protein with Death Domain; FLICE = FADD-like interleukin-1 
beta-converting enzyme; FLIP = Flice-like inhibitory protein; HSC = hematopoietic stem cell; FAS-L = FAS ligand ; INF-γ = interferon gamma; INFsR 
= interferon receptor; iNOS = inducible nitric oxide synthase; IRF-1 = interferon regulatory factor-1; KIR = Killer Ig-like receptors; MDSC = myeloid 
derived suppressor cell; MHC = major histocompatibility complex; NF-kB = nuclear factor kB; NK = natural killer cell; NO = nitric oxide; TCR = T 
cell receptor; TGFβ = transforming growth factor b; TGBR = TGFβ receptor; TH1 = lymphocyte T helper 1; TH17 = lymphocyte T helper 17; TNF-α = 
tumor necrosis factor alpha; TRAIL = TNF–related apoptosis-inducing ligand; TRAIL-R = TNF–related apoptosis-inducing ligand receptor; TRAF2 = 
TNF receptor associated factor 2.




Università degli Studi di Salerno 
favoring MDS progression into AML [43,45]. Concordantly, total marrow Treg levels have been
reported to be inversely related with CD8+ cytotoxic T-
cell recruitment, degree of dyserythropoiesis, and the need 
for erythropoietin treatment [51]. In addition, it has been 
recently described that also high-risk MDS patients with 
normal number of total Treg may often show expansion of 
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), which may promote  MDS clone 
escape from immunosurveillance and finally AML 
progression [50].  Indeed,  increased  Treg EM frequency 
in MDS patients was reported independently associated 
with a higher number of marrow blast cells and decreased 
overall survival [48]. 
The role of Th17 cells in MDS is still controversial. 
Kordasti et al. reported higher levels of Th17 cells in low-
risk MDS patients and their correlation with increased 
apoptosis of marrow hematopoietic cells [41]. 
Conversely, Bouchliou documented decreased numbers 
and functional impairment of Th17 cells in patients with 
low/intermediate-1 risk MDS, and increased numbers in 
patients with intermediate-2/high risk MDS [47]. By 
contrast, concomitant expansion of peripheral Th22 and 
Th17 population have been more recently documented in  
high-risk MDS, as compared to low-risk MDS  patients. 
This finding suggests that these two CD4
+
 Th subsets, 
which mediate the suppression of immune anti-tumor 
responses, may favor MDS clone immune escape during 
MDS progression (Figure 2) [42] .  
In addition to the above mentioned effector cells, that 
are all involved in adaptive immune responses, also cells 
of innate immune responses seem equally contribute to 
the pathogenesis of MDS; they include natural killer (NK) 
cells and myeloid-derived suppressor cells (MDSCs).  
NK cells may mediate inhibition of marrow 
hematopoietic progenitors in low-risk MDS through direct 
killing and production of cytokines, such as IFN-γ and 
TNF-α [52-55].  Higher frequencies of NK cells have 
been documented in low-risk MDS. Moreover, in HMDS 
patients, we found a decreased frequency of long 
cytoplasmic tail of  killer cell immunoglobulin-like 
receptor KIR2DL3, mediating inhibitory signals [56,57]. 






MDSCs, which play an important role in 
suppressing T-cell responses during inflammation and in 
cancer, were markedly expanded in blood and marrow of 
MDS patients, contributing both to ineffective 
granulopoiesis of MDS patients, through the production 
of inflammatory molecules, such as TGF-β, NO, IL-10 
and arginase, and to promoting T cell tolerance favoring 
MDS progression [58-61].  
 
Cytokine dysregulation 
Expression and secretion profile of multiple 
cytokines, such as tumor necrosis factor alpha (TNF-α), 
TNF–related apoptosis-inducing ligand (TRAIL), IFN-γ, 
Flice-like inhibitory protein (FLIP), transforming growth 
factor beta (TGF-β), IL4, IL6, IL10 and IL17, produced 
by the above described immune effector cells and other 
components of microenvironment, have been found 
dysregulated in some MDS, further suggesting their 






 T lymphocytes, mainly from low-
risk MDS patients, consistently show higher expression of 
TNF-α, as compared to healthy controls; in addition, 
increased serum levels of this cytokine has been 
documented in lower risk MDS [17,63,64]. Furthermore, 
TRAIL,  usually not expressed by healthy marrows cells, 
is overexpressed in MDS cells inducing preferentially 
apoptosis of cytogenetically dysplastic cells by 
upregulating their agonistic receptors 1/2 and likely 
downregulating expression and/or function of long 
isoform of the cytoplasmic inhibitor of apoptosis FLIP 
[65,66]. Interestingly, when we analyzed polymorphisms 
at positions -308 of the promoter region of TNF-α, we 
found in MDS patients a high frequency of G/A genotype, 
which has been associated with increased expression and 
production of TNF-α [56].   
IFN-γ, has been frequently found overexpressed in 
marrow and peripheral blood cells from low-risk MDS 
patients, as above described; in addition, IFN-γ has been 
even more frequently found increased in the serum of 
these patients. On the other hand, we have previously 
documented that in vitro blockade of IFN-γ improves 
autologous marrow colony formation in HMDS and RA 
patients [17,56].  Furthermore, elevated IL-12 and IL-17 





 T lymphocytes, were recently described in 
lower-risk MDS patients [67]. Noteworthy, IFN-γ, in case 
of inhibition of interferon regulatory factor-1 (IRF-1), a 
tumor suppressor gene frequently inactivated in high risk 
MDS, may induce aberrant stimulatory signals in MDS 
clone [18,53,54]. Conversely, high levels of IRF-1 have 
been found associated with a favorable prognosis and an 
increase of autoimmune phenomena in MDS [68]. 
However, in contrast to AA patients, we did not find, 
using single nucleotide polymorphisms (SNPs) analysis, 
increased frequencies of the hypersecretory genotype T/T 
of the IFN-γ both in HMDS and normo/hypercellular 
MDS [56]. 
In addition to IFN-γ and TNF-α, TGF-β  is reported 
to be another potent inhibitor of hematopoiesis triggering 
apoptosis of both early and late hematopoietic 
progenitors.  Both TNF-α and IFN-γ, as well as, TGF-β 
may stimulate the expression of inducible nitric oxide 
synthase (iNOS) by normal MDS cells and marrow 
microenvironment, contributing to ineffective 
hematopoiesis in MDS [17,52,53,69].  IFN-γ, TNF-α, and 
TGF-β can all induce apoptosis of primary human 
hematopoietic progenitors mediated by p38 mitogen-
activated protein kinase (MAPK), which has been found 
overexpressed in low-risk MDS [69-71]. 
Moreover, direct evidence of hyperactivation of the 
TGF-β pathway in MDS has been recently proven by 
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showing  that smad2, a downstream mediator of  TGF-β 
receptor I kinase (TBRI) activation, is overexpressed in 
gene expression profiles of MDS CD34
+
 cells and is 
constitutively activated in marrow progenitors of low-risk 
MDS patients [69]. Noteworthy, as previously 
documented for AA patients, when we examined the 
frequency of TGF-β polymorphisms, MDS population 
showed a higher rate of GG codon 25 variant genotype 
and of TT codon 10 variant, consistent with a high 
secretory phenotype [56]. When MDS patients were 
subdivided according to marrow cellularity, we found that 
hypocellular MDS were characterized by a higher 
prevalence for G/G genotype, further suggesting that 
immune-mediated mechanisms similar to those seen in 
AA patients may also operate in hypoplastic MDS 
patients, leading to depletion of early and late 
hematopoietic progenitor cells [56].  
In HMDS patients, but not in AA patients, analysis of 
promoter polymorphisms of IL-10 showed increased 
prevalence of G/A genotype variant at position –1082, 
functionally associated with decreased production of IL-
10 levels [56]. Defective IL-10 levels frequently 
described in low-risk MDS may allow enhanced 
production of Th1 cytokines responsible for increased 
apoptosis and decreased progenitor cell differentiation 
and proliferation in MDS patients. Conversely, high 
serum levels of IL-10, inhibiting T-cell mediated immune 
responses, have been reported in high-risk patients 
(Figure  2) [72]. 
III. CURRENT IMMUNOSUPPRESSIVE 
STRATEGIES IN MDS 
 
Immunosuppression with horse antithymocyte 
globulin (ATG) and cyclosporine A (CyA) is the standard 
of care for AA patients lacking a low-risk transplant 
procedure, resulting in a durable overall response rate 
(ORR) in about 60-70% of patients [73].  
Immunosuppression was first used with some success 
in HMDS patients and then also applied to normo-  or 
hyper-cellular MDS [74,75].  Since about half of all 
deaths in low-risk MDS are related to complications of 
cytopenia rather than leukemic evolution, 
immunosuppression in such studies has been widely used 
in  these subtypes of MDS patients [3,6].  
Main studies with current immunosuppressive 
treatments in MDS patients are summarized in Table 1. 
However, as a complete discussion on the results of the 
immunosuppresssion in MDS patients is beyond the scope 
of this article, the reader is referred to others extensive 
review on this topic [3,6,76-78].  
CyA-based treatment studies have documented that 
CyA induces, both in hypocellular and normo-/ hyper-
cellular MDS patients, fast (cumulative time to response 2 
months) and sustained (about 2 years) hematological 
improvement in about 60% of MDS (cumulative ORR: 
62%, range 8-82%) with an estimated overall survival 




































median or (range) 
months) 
Molldrem, 1997 25 56 (24-81) ATG NR 44 44 NR 10 
Jonasova,1998 17 57 (22-85) CyA 53 82 94  3  NR 
Raza, 2001 83 67 (42-87) Thalidomide 15 19 12 4  10.2  
Molldrem, 2002 61 60 (27-81) ATG 38 34 34 2.5 36  
Selleri,2002 11 54 (33-78) CyA 100 73 54 2.3  58.5  
Yazji,2003 32 59 (28-79) ATG+CyA NR 26 6 2.5 12  
Killick,2003 30 54.5 (31-73) ATG 27 33 33 NR 15.5  
Shimamoto,2003 50 55 CyA 20 60 50 1.8  NR 
Deeg, 2004 15 67 (32-81) ATG + etanercept 7 46 33 NR (24-36) 
Raza, 2004 37 68 Remicade NR 22 NR NR (6-12) 
Stadler,2004 35 63 (41-75) ATG 11 34 20 3  9  













31 4 36  
Garg,2009 15 63 (42-80) ATG+CyA NR 33 NR 3.7  NR 
Scott, 2010 25 64 (53-85) ATG + etanercept NR 56 NR 2 (5-36) 
Sloand,2010 31 57 (23-72) Alemtuzumab 35 68 29 3 NR 
Xu, 2010 37 NR CyA+Thalidomide NR 38 NR 19.5  NR 
Passweg, 2011 45 62 (23-75) ATG+CyA 20 29 NR NR 16.4 
Xiao, 2011 37 44 (21-70) CyA+Thalidomide 14 57 41 1.8  22  
Xiao, 2011 80 41 (12-75) CyA 48 77.5 34 1.5  24 
Kadia,2012 24 62 (41-78) ATG+CyA NR 25 NR 4  NR 
Abbreviations. ATG = antithymocyte globulin; CyA = cyclosporine A; HMDS = hypoplastic myelodysplastic syndrome; NR = not reported; ORR = 
overall response rate, resulted from complete remission + partial remission + hematological improvement; OS = overall survival. Ref. [67-86]. 
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transfusion independence  in 58% of MDS patients. CyA 
was generally well tolerated, requiring  drug withdrawal 
in a minority of patients, most of whom due to renal 
toxicity. However, we and others documented even higher 
hematological responses in hypocellular MDS [17,75,79-
81].   
Various clinical trials have investigated the role of  
horse (h) or rabbit (r) ATG alone [74,80,82-84] and in 
combination with CyA in MDS [80,85-89]. 
Approximately 30% of younger patients with lower risk 
MDS, expressing the HLA-DR15 allele and showing 
hypocellular bone marrow, achieved a rapid (time to 
response about 2.8 months) and prolonged hematological 
response with an estimated OS of 41 months [74,80,82-
89]. As reported by the largest ATG-based treatment 
study of National Institutes of Health (NIH) on MDS, 
combination therapy of ATG with CyA, in comparison to 
ATG alone, is able both to further improve hematological 
responses allowing to achieve approximately 44% of 
ORR and to decrease the relapse rate [80]. In this and 
other ATG-based treatment study it has been reported that 
MDS patients relapsing post-ATG may be again 
responsive to CyA treatment [3,6].   
In contrast to AA, although the comparative efficacy 
of hATG versus rATG has not been formally studied in 
MDS, it seems that there is no significant difference 
between the two sources of ATG in terms of 
hematological  responses or adverse effects [84,90]. In 
addition, both CSA- and ATG-based treatments appeared 
do not increase progression to acute leukemia. 
Alemtuzumab is an anti-CD52 monoclonal antibody, 
which has been successfully used in the treatment of AA 
patients failing initial immunosuppression with ATG and 
not eligible for transplant [91]. Recently, alemtuzumab 
monotherapy was used in a pilot study of 32 MDS 
patients, selected on the basis of likely responsiveness to 
immunosuppression due to  younger age, low IPSS score, 
and the presence of HLA-DR15. A sustained  ORR was 
documented among 77% and 57% of patients with 
intermediate-1 and intermediate-2 MDS, respectively, 
with a median time to response of about 3 months. 
Noteworthy, four of seven patients with karyotypic 
abnormalities at diagnosis had complete cytogenetic 
remission, including one patient with monosomy 7 [92]. 
In addition, we should mention that the therapeutic 
TNF-α blockade with anti-TNF-α monoclonal antibodies, 
soluble TNF-α receptors, and chemical inhibitors of TNF, 
such as thalidomide, have been disappointing when used 
as monotherapy [93-97]. More recently, combination of 
thalidomide with CyA [98,99], as well as of soluble TNF-
α receptor etanercept with ATG [100,101] in MDS 
patients seems to increase hematological responses in 





Distinguishing HMDS from AA is clinically relevant 
since  the incidence of progression to acute leukemia is 
higher in HMDS. Differential diagnosis between these 
two diseases is still challenging, especially when 
dysplastic cells are difficult to detect due to marked 
hypocellularity of specimens and karyotipic abnormalities 
are not found. Also the more advanced SNP technology 
do not help to differentiate between these two diseases 
given that similar molecular abnormalities may be 
detected both in AA and MDS, including HMDS. 
The autoimmune pathogenesis of MDS, including 
HMDS, is multifactorial and still unraveled. Several 
laboratory and clinical studies have provided evidence 
that some MDS seem likely to be related to  derangement 
in the complex cross-talk between immunological 
microenvironment and marrow hematopoietic stem cells, 
resulting on one side in ineffective hematopoiesis related 
to immune-mediated apoptosis of normal hematopoietic 
progenitors, and on the other side in triggering clonal 
expansion of dysplastic progenitor cells leading to acute 
leukemia development.  
Mechanisms of immune damage of hematopoietic 
progenitors, mediated by increased numbers of CTL,  
IFN-γ producing CD4
+
 cells and Th17 cells, increased 
levels of pro-apoptotic cytokines, as well as by decreased 
numbers of  Treg, are predominantly involved in HMDS 
and low-risk MDS. By contrast, mechanisms developing 
an immunosuppressive marrow microenvironment 
favoring MDS clone escape, mainly associated with 
increased numbers of TregEM, MDSCs and  anti-
apoptotic cytokines,  as well as with NK cell dysfunction, 
may contribute to high-risk MDS and acute leukemia 
progression.  
Clinically, the best evidence for immune-mediated 
impairment of hematopoietic progenitor cell compartment 
in MDS patients is the improvement of peripheral 
cytopenia and survival after CyA- and ATG- based 
regimens, or alemtuzumab. Although the response to 
immunosuppression has been documented more often in 
HMDS patients, it may occurs also in lower-risk MDS 
patients. Other predictive factors recognized for response 
to immunosuppression in MDS include mainly younger 
age, HLA-DR15 expression, shorter duration of red cell 
transfusion dependence [102] and  trisomy 8.  
Based on the mechanisms described above, such 
better understanding  of innate and adaptive immune 
responses involved in MDS pathophysiology, may pave 
the way for the development of novel immunotherapeutic 
approaches. Indeed, therapeutic strategies interfering with 
immune-mediated apoptosis of hematopoietic progenitor 
cell compartment in lower risk MDS and with immune-
evasion of MDS clone in higher risk MDS, are already 
under evaluation in phase I/II clinical trials and are 
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